Literature DB >> 24766367

Economic challenges associated with tuberculosis diagnostic development.

Colleen F Hanrahan1, Maunank Shah.   

Abstract

Tuberculosis remains a global health crisis in part due to underdiagnosis. Technological innovations are needed to improve diagnostic test accuracy and reduce the reliance on expensive laboratory infrastructure. However, there are significant economic challenges impeding the development and implementation of new diagnostics. The aim of this piece is to examine the current state of TB diagnostics, outline the unmet needs for new tests, and detail the economic challenges associated with development of new tests from the perspective of developers, policy makers and implementers.

Entities:  

Keywords:  diagnostic development; diagnostics; economic evaluation; tuberculosis; tuberculosis control policy

Mesh：

Year:  2014        PMID： 24766367      PMCID： PMC4605384          DOI： 10.1586/14737167.2014.914438

Source DB:  PubMed          Journal:  Expert Rev Pharmacoecon Outcomes Res        ISSN： 1473-7167            Impact factor:   2.217


  50 in total

Review 1.  Point-of-care diagnostics for HIV and tuberculosis: landscape, pipeline, and unmet needs.

Authors:  Nitika Pant Pai; Madhukar Pai
Journal:  Discov Med       Date:  2012-01       Impact factor: 2.970

2.  Cost-effectiveness of Xpert® MTB/RIF for diagnosing pulmonary tuberculosis in the United States.

Authors:  H W Choi; K Miele; D Dowdy; M Shah
Journal:  Int J Tuberc Lung Dis       Date:  2013-10       Impact factor: 2.373

3.  Cost-effectiveness of routine diagnostic evaluation of pulmonary tuberculosis in a primary care unit in Brazil.

Authors:  R L Guerra; S E Dorman; R R Luiz; M B Conde
Journal:  Int J Tuberc Lung Dis       Date:  2013-10       Impact factor: 2.373

4.  Cost-effectiveness of novel algorithms for rapid diagnosis of tuberculosis in HIV-infected individuals in Uganda.

Authors:  Maunank Shah; David Dowdy; Moses Joloba; Willy Ssengooba; Yukari C Manabe; Jerrold Ellner; Susan E Dorman
Journal:  AIDS       Date:  2013-11-28       Impact factor: 4.177

5.  Diagnostic accuracy and effectiveness of the Xpert MTB/RIF assay for the diagnosis of HIV-associated lymph node tuberculosis.

Authors:  A Van Rie; L Page-Shipp; K Mellet; L Scott; M Mkhwnazi; E Jong; T Omar; N Beylis; W Stevens; I Sanne; C N Menezes
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-05-10       Impact factor: 3.267

6.  Challenges in evaluating the cost-effectiveness of new diagnostic tests for HIV-associated tuberculosis.

Authors:  Jason R Andrews; Stephen D Lawn; David W Dowdy; Rochelle P Walensky
Journal:  Clin Infect Dis       Date:  2013-06-20       Impact factor: 9.079

7.  Comparison of quantitative techniques including Xpert MTB/RIF to evaluate mycobacterial burden.

Authors:  Richard N van Zyl-Smit; Anke Binder; Richard Meldau; Hridesh Mishra; Patricia L Semple; Grant Theron; Jonathan Peter; Andrew Whitelaw; Suren K Sharma; Robin Warren; Eric D Bateman; Keertan Dheda
Journal:  PLoS One       Date:  2011-12-22       Impact factor: 3.240

8.  Diagnostic accuracy of a low-cost, urine antigen, point-of-care screening assay for HIV-associated pulmonary tuberculosis before antiretroviral therapy: a descriptive study.

Authors:  Stephen D Lawn; Andrew D Kerkhoff; Monica Vogt; Robin Wood
Journal:  Lancet Infect Dis       Date:  2011-10-17       Impact factor: 25.071

9.  Determine TB-LAM lateral flow urine antigen assay for HIV-associated tuberculosis: recommendations on the design and reporting of clinical studies.

Authors:  Stephen D Lawn; Keertan Dheda; Andrew D Kerkhoff; Jonathan G Peter; Susan Dorman; Catharina C Boehme; Mark P Nicol
Journal:  BMC Infect Dis       Date:  2013-09-03       Impact factor: 3.090

10.  HIV-associated tuberculosis: relationship between disease severity and the sensitivity of new sputum-based and urine-based diagnostic assays.

Authors:  Stephen D Lawn; Andrew D Kerkhoff; Monica Vogt; Robin Wood
Journal:  BMC Med       Date:  2013-10-29       Impact factor: 8.775
View more
  4 in total

1.  Antigens Rv0310c and Rv1255c are promising novel biomarkers for the diagnosis of Mycobacterium tuberculosis infection.

Authors:  Liulin Luo; Lin Zhu; Jun Yue; Jianping Liu; Guoyuan Liu; Xuelian Zhang; Honghai Wang; Ying Xu
Journal:  Emerg Microbes Infect       Date:  2017-07-12       Impact factor: 7.163

2.  Gaps related to screening and diagnosis of tuberculosis in care cascade in selected health facilities in East Africa countries: A retrospective study.

Authors:  Nicholaus P Mnyambwa; Doreen Philbert; Godfather Kimaro; Steve Wandiga; Bruce Kirenga; Blandina Theophil Mmbaga; Winters Muttamba; Irene Najjingo; Simon Walusimbi; Roseline Nuwarinda; Douglas Okelloh; Hadja Semvua; James Ngocho; Mbazi Senkoro; Okoboi Stephen; Barbara Castelnuovo; Aman Wilfred; Erick Mgina; Cassiana Sanga; Fredrick Aman; Amosi Kahwa; Sayoki Mfinanga; Esther Ngadaya
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2021-09-22

Review 3.  Rapid Molecular Assays for the Diagnosis of Drug-Resistant Tuberculosis.

Authors:  Louansha Nandlal; Rubeshan Perumal; Kogieleum Naidoo
Journal:  Infect Drug Resist       Date:  2022-08-29       Impact factor: 4.177

Review 4.  PET/CT imaging of Mycobacterium tuberculosis infection.

Authors:  Alfred O Ankrah; Tjip S van der Werf; Erik F J de Vries; Rudi A J O Dierckx; Mike M Sathekge; Andor W J M Glaudemans
Journal:  Clin Transl Imaging       Date:  2016-03-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.